The Latest Breaking News from BMO

BMO Alto offers high-yield savings accounts and CDs with competitive rates and no fees, making it a solid choice for online banking enthusiasts.

Explore BMO Financial Group's CD options, including Special CDs and Alto CDs with competitive rates. Consider minimum deposits, online-only limitations, an...

Before you bank with BMO, take stock of the APYs and monthly fees on their accounts.

BMO, RBC, Wedbush, Needham, and Piper Sandler analysts weigh in on Azure growth, AI potential, and market reaction.

Goguigo_Tatolino has created a custom BMO using a Raspberry Pi that both plays games and functions as a desktop.

‘A recruitment process works both ways,’ she says

The bank is aspiring to national reach, so it is dropping the Harris name and Hubert, its longtime symbol.

ST. PAUL, Minn. — BMO Financial Group must pay the bankruptcy trustees of Tom Petters $563.7 million in damages for the role a predecessor bank played in the multibillion-dollar fraud by the Minnesota businessman, a federal jury in St. Paul ruled Tuesday.

Workday, Inc (NASDAQ:WDAY) clocked 21.9% revenue growth in Q2 to $1.54 billion, which beat average analyst estimates. The subscription revenues of $1.37 billion were up 22.8%.  Workday reported EPS of $0.83, which beat average analyst estimates. Workday reported solid 2Q23 results highlighted with an uncertain macro backdrop pressuring sales much less than feared, Needham analyst…

Analysts remained divided with a cautious tone over SAP SE's (NYSE:SAP) prospects post Q2 results. Barclays analyst Raimo Lenschow saw SAP managing expectations into Q2, and the move lower in consensus halved the adj. EBIT miss.  He found the FY guidance cut was unexpected, though, especially following reiterations in the quarter, and could not…

BMO Capital initiated coverage of Intellia Therapeutics Inc (NASDAQ:NTLA) with a Market Perform rating and a $54 target price.  The analyst says Intellia's gene-editing platform could potentially deliver transformative therapies.  But challenges around the lack of clarity around an IND approval in the U.S., ongoing CRISPR/Cas9 IP litigations with Editas Medicine Inc (NASDAQ:EDIT), and high patient…